Clinical Trial Update: A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) [Phase 3]

View source ↗

Summary

Eli Lilly is conducting a Phase 3 pediatric study (AWARD-PEDS PLUS) evaluating dulaglutide at 3.0 mg and 4.5 mg in children with type 2 diabetes mellitus. The t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• TRULICITY (DULAGLUTIDE)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes | Phase 3 | Status: RECRUITING